SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Boy in a wheelchair looking out the window
Neurodegenerative disease
Biohaven Sets Stage for Comeback With Pivotal Study Results in Spinocerebellar Ataxia
The FDA previously refused to review Biohaven’s candidate in the indication due to a failed late-stage trial. However, the company is now planning to file an NDA in the fourth quarter of 2024.
September 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Legal
Amgen Gets Legal Win in Eylea Patent Row With Regeneron
Regeneron’s lawsuit, filed earlier this year, alleged more than 30 counts of patent infringement against Amgen and its biosimilar to the blockbuster eye therapy Eylea.
September 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Biogen’s headquarters in Massachusetts
Immunology and inflammation
Biogen, UCB Score Phase III Lupus Victory After Mid-Stage Stumble
Stifel analyst Paul Matteis called Tuesday’s readout a “positive surprise” that could reinvigorate some investor enthusiasm for Biogen as the company “has essentially become an out-of-favor value stock,” driven by the slow launch of its Alzheimer’s disease therapy Leqembi.
September 24, 2024
 · 
2 min read
 · 
Tristan Manalac
VIP Event at the Bioprocessing Summing 2024
Business
The White House, Microsoft, SAS, Foley Hoag & Astellas Offer AI Guidance to Investors. Part Two: The Future
As technology continues to evolve, companies should have strategies that incorporate an understand of where they are now, where they want to be, and do they have the talent to get there.
September 24, 2024
 · 
6 min read
 · 
Lori Ellis
United States Capitol Building & dollar bills /
Policy
Novo CEO, Sanders to Face Off Over US Prices for Ozempic and Wegovy
In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard Jørgensen will be asked to defend the drugs’ U.S. monthly list prices of $969 and $1,349, respectively.
September 24, 2024
 · 
3 min read
 · 
Greg Slabodkin
Covid-19, Coronavirus vaccine in vial with syringe on blue earth map background
Opinion
Mpox Is Back. Here’s How to Involve Industry in the Response
Regulators, policymakers and others can more effectively battle the disease by creating incentives to make mpox a more attractive investment opportunity.
September 24, 2024
 · 
5 min read
 · 
Giulia Balconi
From Left to right: Lori Ellis, Sherrine Eid, Colin Zick, Nagisa Sakurai, Mike Walker, Sarah Glaven
Business
The White House, Microsoft, SaS, Foley Hoag & Astellas Offer AI Guidance to Investors. Part One: The Present
Before companies and investors look towards the future, they must first understand the opportunities and challenges AI presents to them. From the benefits included in advancing processes to cybersecurity hazards, AI innovation is a balanced scale of oppportunities and risks.
September 23, 2024
 · 
10 min read
 · 
Lori Ellis
Group of employees being laid off by their company
Layoffs
Athira Pharma to Lay Off 70% of Workforce
Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.
September 23, 2024
 · 
1 min read
 · 
Angela Gabriel
Pictured: A Bristol Myers Squibb among some bushes
Layoffs
BMS Will Lay Off 79 in Lawrenceville, NJ, Bringing City’s Employee Cuts to 1,134
Bristol Myers Squibb is continuing its cost-savings measures with layoffs in Lawrenceville, New Jersey. The company announced earlier this year that it will eliminate 2,200 jobs by the end of 2024 in a bid to save $1.5 billion through 2025.
September 23, 2024
 · 
2 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS